So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily blocked by a federal appeals court as it considers the drugmaker's ...

Novartis has responded to the inclusion of its heart failure blockbuster Entresto on the list of the first 10 drugs that will be subject to Medicare pricing negotiations, claiming that the move ...

Novartis took its campaign to invigorate sluggish sales of its new heart-failure medicine Entresto to a U.S. cardiologists meeting on Saturday, telling attendees that even clinically stable ...

A Novartis executive said the Swiss company's heart failure medicine Entresto could be used more widely in future, potentially making it a blockbuster drug with revenue potential of $4 billion to $5 ...

Marketing ESC need-to-know: Xarelto flops, Pfizer’s tafamidis wins, Entresto’s early use and more By Angus Liu Aug 27, 2018 12:10pm ...